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Abstract
Mutations in DNA repair enzymes can cause two neurological clinical manifestations: a developmental impairment
and a degenerative disease. Polynucleotide kinase 3′-phosphatase (PNKP) is an enzyme that is actively involved in
DNA repair in both single and double strand break repair systems. Mutations in this protein or others in the same
pathway are responsible for a complex group of diseases with a broad clinical spectrum. Besides, mitochondrial
dysfunction also has been consolidated as a hallmark of brain degeneration. Here we provide evidence that supports
a shared role between mitochondrial dysfunction and DNA repair defects in the pathogenesis of the nervous system.
As models, we analyze PNKP-related disorders, focusing on Charcot-Marie-Tooth disease and ataxia. A better
understanding of the molecular dynamics of this relationship could provide improved diagnosis and treatment for
neurological diseases.
Keywords: DNA repair, Mitochondrial dysfunction, Neurodegeneration, Ataxia, PNKP
Background
The present review aims to expand knowledge in the
pathological process that involves defects in DNA
repair and its interaction with mitochondrial dys-
function in neurodegeneration. Recently, evidence
has grown on the involvement of mitochondrial dys-
function in neurodegenerative diseases of the central
nervous system, such as Alzheimer’s and Parkinson’s
and peripheral nervous system as well. Our team has
worked mainly on the molecular causes of peripheral
neuropathies that are classified as Charcot-Marie--
Tooth disease (CMT). We identified a group of pa-
tients with mutations in the PNKP gene, an essential
nuclear and mitochondrial DNA repair enzyme. Mu-
tations in this gene have been associated with a
pathological spectrum, varying from a neurodevelopmen-
tal impairment to a neurodegenerative disease. In this re-
view, we analyze the existing literature that supports a
pathological interaction between DNA repair and mito-
chondria, that causes an exclusive neurological effect, as
in the case of PNKP-associated diseases.
Main text
Nuclear and mitochondrial DNA are susceptible to
damage due to errors of intrinsic DNA metabolism,
and its exposure to radiation, reactive oxygen species
and other environmental factors. Therefore, the
DNA damage response is critical for cell survival
and health [1].
The polynucleotide kinase 3′-phosphatase (PNKP) is
the main enzyme responsible for restoring the
5′-phosphate and 3′-hydroxyl ends in DNA strand
breaks, necessary for ligation during repair, especially
in single strand breaks (SSBs) (Fig. 1) [4–6]. PNKP is
recruited to repair errors in SSBs through interactions
between its N-terminal FHA domain and the X-Ray
Repair Cross Complementing one (XRCC1) protein,
necessary for the recruitment of PNKP and other pro-
teins [7]. In the case of double-strand breaks (DSBs),
PNKP participates, in the non-homologous end join-
ing pathway (NHEJ), which takes place when the
FHA domain interacts with the X-Ray Repair Cross
Complementing 4 protein (XRCC4) [8]. However, it
was also demonstrated that DSBs end-joining reaction
could be dependent on PARP1, PNKP (hPNK) and
the XRCC1/LIG III complex, known as alternative
NHEJ [9].
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SSB repair function in the nervous system: the model of
PNKP in health and disease
Due to its high rate of oxygen consumption, the nervous
system is susceptible to DNA damage, particularly in com-
parison with other tissues that contain non-replicating cell
types. The brain metabolizes ~ 20% of consumed oxygen
but has a low capacity to neutralize reactive oxygen spe-
cies (ROS). Therefore, neurons are particularly susceptible
to oxidative stress [10]. SSBs occur when one strand of
the DNA losses a single nucleotide. If not repaired, it will
represent a severe threat to genetic stability and cell sur-
vival. SSBs are considered the most common damage to
DNA (1000 breaks/cell/day) in the cell [11], mainly de-
rived from reactive oxygen species [12] and commonly
repaired by the PNKP + XRCC1 complex. Since neurons
have low levels of antioxidant enzymes and high transcrip-
tional activity, these cells depend on the single-strand
break repair pathway (SSBR) [13].
SSBR proceeds in four stages: break detection, pro-
cessing of DNA termini, DNA gap filling and ligation
(Fig. 2). In the mature nervous system, genome stability
related mechanisms differ from those operating during
neurogenesis because of the lack of cell division and the
absence of replicative DNA damage and homologous re-
combination repair [14]. Proliferating neural cells are
proficient for DNA damage-induced apoptosis, [15] a re-
source to avoid excessive damage and control cell
growth. In contrast, in post-mitotic cells, including neu-
rons and cardiomyocytes, death by apoptosis is not that
common and requires additional steps [16].
To complete the scenario, double-strand breaks
(DSBs) can occur spontaneously in the brain, because of
the high neuronal activity [17]. Nevertheless, in non-cyc-
ling cells, the homologous recombination system (HR)
that repairs double-stranded breaks is unavailable [14].
Therefore, in post-mitotic neurons, NHEJ is the sole
available pathway to repair this problem [18]. In the ab-
sence of DNA ligase IV, a key NHEJ component, neu-
rons progressively accumulate endogenous DSBs [19].
Thus, in the mature nervous system, strand breaks and
Fig. 1 a Schematic representation of the functional domains of PNKP. We reported five unrelated patients with CMT2 disease, who were compound
heterozygotes for the p.Thr408del (exon 14) and p.Gln517ter * (exon 17) variants [2]. Homozygous individuals for the p.Thr408del variant present
Ataxia-ocular motor apraxia 4 (AOA4) [3]. b Enzymatic role of PNKP. The enzyme catalyzes the 3′-phosphate termini dephosphorylation and the
phosphorylation of 5′-OH terminal by using ATP as the phosphate donor. Mitochondrial-targeting signal (MTS) is a necessary region for
PNKP translocation to mitochondria. FHA: Fork-head-associated domain
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DNA modifications from oxidative damage can disrupt
transcription and lead to cell death [20].
Despite the broad spectrum of diseases associated with
mutations in DNA repair enzymes (such as immunodefi-
ciency and higher cancer risk), defects in the SSBR path-
way present a tendency to affect the nervous system, in
some cases exclusively [21–23]. As PNKP has a vital role
in both nuclear and mitochondrial DNA integrity, muta-
tions in this enzyme or associated proteins, have several
implications in the pathogenesis of neurological diseases.
Until now, two different clinical manifestations have
been associated with PNKP mutations: a neurodevelop-
mental impairment (Microcephaly and Seizures, MCSZ)
and neurodegenerative disorders (i.e., Ataxia-ocular
motor apraxia 4, AOA4) [24]. To illustrate the impact of
DNA Repair Deficiency in neurological manifestations,
we will explain some of the PNKP-associated diseases.
SCA3
Spinocerebellar ataxia type 3 (SCA3) is an autosomal
dominant neurodegenerative disease, and the most com-
mon inherited ataxia worldwide [25]. The disease is
caused by an expansion of a polymorphic CAG trinucle-
otide repeat in the Ataxin 3 (ATXN3) C-terminal coding
region. PNKP interacts with this protein and is inacti-
vated by the mutant form of ATXN3, resulting in ineffi-
cient DNA repair [26]. This leads to an accumulation of
DNA damage due to strand breaks with subsequent
chronic activation of ATM signaling pathway.
MCSZ
Some PNKP mutations cause an autosomal recessive
disease characterized by microcephaly, seizures and de-
velopmental delay and behavioral problems (denoted
MCSZ). In samples of patients severely affected with
MCSZ [24] (family three: homozygous E326K mutation),
and mildly affected individuals (family seven: compound
heterozygous for T424GfsX48 in exon 14 and a 17-bp
deletion in intron 15), concentrations of PNKP protein
was much lower compared with unaffected family mem-
bers. This low concentration was correlated with the se-
verely affected individuals from families 1–6. Although
all these mutations impair PNKP activity, family seven
compound heterozygous individuals, present a slightly
Fig. 2 Basic stages of Single-Strand Break Repair: 1. Detection of the break, 2. DNA end processing, 3. DNA gap filling and DNA ligation, 4. Repaired
strand. Direct breaks are detected by PARP1, which promotes the accumulation of different repair factors. Damaged termini are repaired by APE1, DNA
polymerase (Pol β), PNKP and APTX. Ligase (LIG III) is needed to repair short-patch sites through a phosphodiester bond
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milder phenotype, probably due to a remnant function
of the enzyme. Families four and five presented the same
homozygous Thr424GlyfsX48 mutation.
In mice, a hypomorphic allele that reduces the ex-
pression of PNKP is sufficient for viability but affects
genome integrity [27]. The complete loss of PNKP
resulted in non-viable embryos. Therefore, endogen-
ous DNA lesions cannot be properly repaired, lead-
ing to neural cell loss and resultant neuropathology.
In their experiment, Shimada and colleagues found
that PNKP inactivation resulted in the loss of cere-
bellar neuronal population in an ATM-independent,
but partially p53-dependent manner [27]. Thus, they
suggested that in MCSZ, the errors in neurons asso-
ciated with high oxygen consumption, depend on
PNKP. According to this, it was proposed that like
in other syndromes, the microcephaly in MCSZ
probably implicates defective double-strand break re-
pair (DSBR) [28]. According to this, the instability of
the encoding variants of PNKP rather than specific
mutations causes both microcephaly and neurode-
generation. Thus, the lack of PNKP activity would
be responsible for the mutagenic effects in neurons.
The role of PNKP and DSBs in the etiology of MCSZ
can be supported by the fact that the process of DSBR
needs XRCC4 instead of XRCC1 (involved in SSBs). As
the E236K mutation modifies the phosphatase domain,
the protein is defective in being recruited to DNA dam-
age sites, possibly through decreased interaction with
XRCC4-LigIV complex after DNA damage [29]. One ex-
planation could be that low PNKP-E326K mutant levels
in MCSZ do not result from mRNA instability but cellu-
lar protein instability. However, although this specific
mutation has reduced DNA kinase and DNA phosphat-
ase functions at 37 °C, normal activity was reported at
30 °C [5]. In MCSZ, E326K mutation represents an im-
paired electrostatic interaction between this region and
XRCC4-Lig4 due to an amino acid charge swap [30].
Interestingly, among the seven families studied with
MCSZ [24], the three families that shared a homozygous
mutation that resulted in the E326K change, had the
most severe phenotype, suggesting a major depletion in
the protein functioning.
AOA4
AOA4 is a rare autosomal neurodegenerative disorder
characterized by ataxia, oculomotor apraxia, and periph-
eral neuropathy [3] caused by mutations in PNKP [28].
Muscle weakness progresses until most individuals start
using wheelchairs by the second or third decade [30].
Interestingly, the fact that none of the mutations in
MCSZ or AOA4 eliminates the phosphatase activity of
the enzyme can be an indicator of lethal effect derived
from a complete loss of its function [28]. This can be
explained by the importance of the phosphatase activity
in neurogenesis, since defects related to the 3′-phos-
phate end lack an effective alternative backup pathway.
This lack was recently demonstrated in cancer cells lines
[31]. Most of the mutations in PNKP that cause AOA4
belong to the kinase domain. Despite this, it is compli-
cated to establish a phenotype-genotype correlation due
to the compound heterozygous’ clinical picture. For ex-
ample, Thr424GlyfsX48 mutation is present not only in
MCSZ but in AOA4 [3, 24]. In this line, another case
was also reported, in which two brothers were homozy-
gous for the p.Thr424GlyfsX48 variant in PNKP [32].
They presented a severe progressive polyneuropathy and
cerebellar atrophy, microcephaly, mild epilepsy, and in-
tellectual disability. The authors were not able to estab-
lish a definitive diagnosis since these patients presented
all clinical manifestations reported for PNKP mutations.
Interestingly, mice homozygous for the p.T424GfsX48
allele were lethal at the embryonal stage [27]. Com-
pound heterozygosity involving the p.Thr408del variant
is also common in AOA4 and CMT2B2 patients [2, 3].
Recently, another research reported the case of a woman
affected by AOA4 that also develop a pilocytic astrocy-
toma in the right cerebellar hemisphere [33]. The patient
was compound heterozygous for p.T424GfsX49 /
p.Tyr515ter. From the families affected by MCSZ [24],
affected members of family seven were compound het-
erozygotes, and had the most favorable phenotype, car-
rying a non-coding mutation, which makes it possible to
retain some PNKP activity. According to this, the
phenotype generated by PNKP mutations is subject to
allelic combination effects. Similar to AOA4 other
neurological diseases are caused by mutations in genes
that belong to the SSBR pathway. Ataxia with oculomotor
apraxia-1 (AOA1) is caused by mutations in aprataxin
(APTX), spinocerebellar ataxia with axonal neuropathy-1
(SCAN1) is derived from mutated Tyrosyl-DNA Phospho-
diesterase 1 (TDP1). Since diseases such as AOA and
SCAN1 tend to present a later onset in life, a possible ex-
planation is that some backup mechanisms protect the
cells during development [20]. These cells can even trigger
apoptosis to avoid major damage in the nervous system.
During neural development, progenitor cells undergo
symmetric divisions that expand the size of the progenitor
pool. After that, they will switch to an “asymmetric” mode
of division, wherein each round produces one progenitor
cell and one “postmitotic” neuron [13]. Differentiated cells
can succumb to non-repaired DNA damage, but in this
postmitotic scenario, apoptosis is likely to be avoided since
neuronal cells are unreplaceable. Thus, as a consequence
of the damage produced to this pool of cells, neurodegen-
erative diseases are likely to be related with DNA damage
that cannot be repaired, or a progressive addition of the
continuous damage of the DNA [14].
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Epileptic encephalopathies
A group of epileptic encephalopathies has also been asso-
ciated with PNKP [34, 35]. PNKP contains a C-terminal
mitochondrial-targeting signal (MTS) (Fig. 1). This signal
is needed for the entrance of PNKP to the mitochondria,
through the mitofilin protein. This MTS site, close to the
carboxy-terminus of the protein, locates at codons 432–
441 (ARYVQCARAA). In silico analysis indicated that
mutations in this region would result in a lower affinity of
the MTS “domain” because the protein failed to enter the
mitochondria. Interestingly, the loss of the MTS resulted
in a clear decrease in the PNKP’s activity during mtDNA
repair. Seizures always represent an excessive acute energy
demand, irrespective of their origin in the brain [36]. The
relationship between mitochondria dysfunction and seiz-
ure generation could be deduced from changes in calcium
homeostasis, oxidation of ion channels and neurotrans-
mitter transporters by ROS. Secondary mitochondrial dys-
function is a well-known mechanism in some epileptic
disorders, even for those diseases that are mainly of
non-mitochondrial origin [37].
Many mutations in codons that involved the MTS “do-
main” of PNKP are related to infantile epileptic enceph-
alopathy and other undefined conditions (PNKP[gene] -
ClinVar - NCBI, 2018), and could be hypothesize that
the etiology of the disease is linked to the inability of
PNKP to translocate to neuronal mitochondria, or its
failure to repair errors generated in the mtDNA. It has
also been proposed that mitochondrial transport of Ca2+
has a role in the intracellular sequestration of this ion in
neurons [38]. Due to their importance in the modulation
of neuronal excitability and synaptic transmission,
changes in Ca2+ homeostasis produced by errors in
DNA repair (SSB), could be a direct explanation for the
effects of mitochondrial dysfunction in the generation of
seizures [36].
Mitochondrial common etiology in axonal degeneration:
using CMT as a model
Charcot-Marie-Tooth disease (CMT) is a heteroge-
neous hereditary motor and sensory polyneuropathy,
which is the most common hereditary neuromuscular
disorder. All patterns of inheritance have been related
to CMT, but autosomal-dominant inheritance is the
most common. Clinically, there are demyelinating
(CMT1, CMT4) axonal (CMT2) and intermediate
forms of the disease [39].
Peripheral nerves need an efficient, energetic metabol-
ism to maintain their machinery related to the transport
through axons, which may be as long as 1 m. Proper
mitochondrial functioning is a critical factor for axonal
and myelin formation and maintenance [39]. In fact,
areas with high demands for ATP like synaptic termi-
nals, active growth cones or axonal branches, contain
more mitochondria than other cellular domains [40].
Defects in mitochondrial transport may cause local en-
ergy depletion and toxic changes in Ca2+ buffering that
may trigger synaptic dysfunction [41]. The damage in
the mitochondria transport system causes a similar path-
ology as those derived from primary mitochondrial im-
paired function. Both mechanisms lead to metabolic
deficiencies, oxidative damage, cytotoxicity, and apop-
tosis [42]. This can affect the neuromuscular junction
and lead to various forms of neuropathy, neurodegenera-
tion, muscular dystrophy and paraplegia. In mature
axons of cultured hippocampal neurons, an average
transport velocity of approximately 0.5 μm/s was re-
ported [43]. Assuming the same for motor axons, mito-
chondrion would reach its synaptic target in
approximately 23 days [42]. Thus, the combination of
distance and volume, seen from the intracellular trans-
port system, could be the “Achilles heel” of neurons and
axons [44]. In this context, we emphasize that mitochon-
drial transportation impairment is crucial in the process
of axonal damage in CMT2 (Fig. 3a). Axonal peripheral
neuropathy could also develop a secondary demyelinat-
ing phenotype. Even in that case, it is well known that
proper mitochondrial functioning is a critical factor for
myelin formation and maintenance [39]. The following
genes have been involved in mitochondria-related axonal
degeneration in CMT:
KIF5A
Kinesin Heavy Chain (KIF5A) mutations can cause axon
degeneration limited to the peripheral nervous system
[46]. This protein is implicated in the transport of mito-
chondria from the neural soma to the axon terminal. The
first relationship between CMT and KIF5A was reported
by [47]. These mutations were also found in Spastic para-
plegia type 10 (SPG10). A single KIF5A mutation was also
detected in a diagnosed CMT2 patient belonging to an
SPG10 family [48]. In zebrafish, KIF5Aa mutants (hetero-
zygous), exhibit a similar phenotype to CMT2, including
the axonal degeneration. In addition, dominant homozy-
gous mutant showed a peripheral sensory axons mito-
chondria deficiency and degeneration [49].
GDAP1
The Ganglioside-induced differentiation-associated protein
1 (GDAP1) is a mitochondrial fission factor mutated in
CMT4 [50]. Mutations can cause perturbed axonal trans-
port, and this may lead to impaired energy production. This
process is also known in other neurodegenerative diseases
due to mutations in genes related to mitochondrial dynam-
ics [51]. Patients with recessive mutations usually have a se-
vere axonal neuropathy with onset in early childhood. In
contrast, patients with dominant GDAP1 mutations usually
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have a mild axonal neuropathy with later onset and
slower disease progression [52]. A reduced intracellular
antioxidant glutathione (GHS) concentration and re-
duced mitochondrial membrane potential were found
in patients with GDPA1 mutations [53]. Therefore, an
implication of oxidative stress in the pathogenesis of
the disease is suggested.
Mutations in GDAP1 can lead to mild, persistent oxi-
dative stress in the peripheral nervous system. However,
the high oxidative stress can be compensated in the un-
affected central nervous system by GDAP1L1 [54]. This
protein acts in response to elevated levels of oxidized
glutathione, by translocating from the cytosol to mito-
chondria, an essential process to substitute the loss of
GDAP1 expression.
MFN2
Mitofusin 2 (MFN2) is a protein from the outer mito-
chondria membrane that participates in mitochondrial
fusion. MFN2 is also necessary for axonal mitochondrial
transport [55]. In a later work, the authors suggested
that although the role of MFN2 mutations in CMT2
pathogenesis is not clear, axonal degeneration could be
explained due to the abnormal transport of mitochondria
through the microtubule system [56]. Thus, that mechan-
ism could explain the peripheral neuropathy and possibly
the pyramidal tract involvement, where the longest axons
are the first and the main ones to be affected. It is interest-
ing that both the mutations in GDAP1 associated with
mitochondrial fission and MFN2, associated with mito-
chondrial fusion; generate a mainly axonal CMT pheno-
type. The underlying cause could be deregulation in the
mitochondrial dynamics, either due to the inability to be
transported through the axons or due to an in-situ dys-
function caused by the disruption of mitochondrial
homeostasis. This allows us to propose the hypothesis of
the involvement of PNKP in the regulation of the integrity
of mtDNA and the pathogenesis of CMT2. An idea that
we will develop later.
There is enough evidence about pathogenic mutations
that disrupt the mitochondrial homeostasis in the sce-
nario of axonal damage. A particular case of mutations
that affect mtDNA integrity is the group of mutations in
the mitochondrial specific DNA polymerase (POLG).
These mutations can cause an autosomal recessive
ataxia-neuropathy syndrome, with onset in the first three
decades of life [57]. This ataxia, named mitochondrial-
associated ataxia syndrome (MIRAS), is caused by
Fig. 3 Integrative representation showing the mitochondrial dysfunction as an etiology of the axonal degeneration. a Mutations associated with
mitochondrial dynamics can cause axonal damage in CMT2 phenotype. b Role of PNKP in the maintenance of mtDNA stability. When PNKP is
mutated, ROS/NOS generate an environment of genotoxic stress, that can impair the normal axonal function. Since the glycolytic capacity of
neurons is restricted, mitochondrial oxidative phosphorylation is essential for neuronal ATP supply [36]. ATM-dependent phosphorylation of PNKP
at serines 114 and 126 in response to oxidative DNA damage inhibits degradation of PNKP. This PNKP stability is required for DNA repair [45].
ATM can also activate p53 which undergoes apoptosis in the presence of high levels of mtDNA damage. ER: endoplasmic reticulum. OXPHOS:
oxidative phosphorylation
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multiple mtDNA deletions. Symptoms include periph-
eral neuropathy, myoclonus, and epileptic seizures. The
replication defects derived from mutations in POLG
affect components of the mtDNA-encoded electron
transport chain and oxidative phosphorylation [14].
The dysfunction of the mitochondrial network also
has a critical role in diseases like chemotherapy-induced
peripheral neuropathies (CIPN). The effects of chemo-
therapeutic drugs on mitochondria in the peripheral ner-
vous system have three principal axes of impairment:
calcium signaling, reactive oxygen species (ROS) and
apoptosis [58]. In an experimented with the WldS mu-
tant mouse that expresses a chimeric nuclear protein
Nmnatl, a protective role of this protein was shown due
to an inhibition of axonal degeneration. This axonal
damage was mainly caused during rotenone and vincris-
tine treatment [59]. This suggests that this protein pro-
tects axons by reducing ROS accumulation or toxicity.
Neurons treated with vincristine in the dorsal root gan-
glia (DRG) decreases the rate of mitochondrial dynam-
ics, including fusion, fission, and motility; and this led to
mitochondrial fragmentation and visible axon degener-
ation [60]. Interestingly, overexpression of an agent
called cytNmnat1 inhibited the axon degeneration by
preserving the normal mitochondrial dynamics. If this
approach can be tested in patients affected with axonal
degeneration, like CMT2B2, a possible future thera-
peutic target is in sight.
PNKP mutations could lead to disease through
mitochondrial dysfunction
As previously mentioned, functionally active full-length
PNKP is present in mitochondria as well as nuclei [69]. The
idea about the contribution of mitochondria dysfunction in
neurological disease is not new, not even in CMT. The con-
tributions of the principal mutations in CMTaffecting mito-
chondrial homeostasis have been extensively reviewed [39,
61], so the role of mitochondria in distal axonal degener-
ation in different peripheral neuropathies [62].
The local energy demand is known to be different be-
tween neuronal compartments, and it tends to change
over time. The peripheral terminals of sensory axons
represent sites of an exceptionally high ATP demand
during conduction [40]. Axons consume high amounts
of ATP, especially to fuel the sodium/potassium ATPase
or sodium pump that functions to remove the sodium
ions that enter the axon during impulse activity [63]. Be-
cause of their energy demand, most neuronal mitochon-
dria reside in axons and dendrites [64]. As neurons
cannot switch to glycolysis when oxidative phosphoryl-
ation (OXPHOS) becomes limited, mitochondrial
transport, together with the dynamic processes of mito-
chondrial fission and fusion, facilitates the transmission of
energy across long distances [65]. Whereas mitochondria
play a crucial role in axonal function, it has been proposed
that mtDNA is more susceptible to oxidative damage be-
cause of its lacks of protective histones [66]. Another fact
is that in contrast to nDNA, almost all mtDNA is tran-
scribed. Therefore, unrepaired mutations in the mtDNA
could alter energy production and are expected to influ-
ence cell homeostasis. Thus, mtDNA genomic stability is
critical for neuronal functioning [67]. The location of the
mitochondria at the nerve terminals is the possible re-
sponsible for the increased susceptibility damage [68].
This vulnerable situation can be associated with age-re-
lated dysfunction and oxidative damage when compared
with non-synaptic mitochondria.
In this regard, mitochondrial PNKP may play a critical
role: PNKP depletion was observed to cause a significant
decrease in mtDNA repair. The full restoration of repair
of the H2O2-induced strand breaks in mitochondria re-
quired both the kinase and phosphatase activities of PNKP
[69] (Fig. 3b). The authors concluded that PNKP plays a
major role in the repairing of oxidized bases in the mito-
chondrial genome. Indeed, the major source of mtDNA
lesions derives from the vast quantities of ROS produced
in the mitochondria during respiration [68]. If this damage
is not repaired, the mitochondria will not be able to func-
tion properly, and this can lead to neuropathy.
In the mitochondria, the base excision repair (BER)
and SBBR pathways are the primary DNA repair mecha-
nisms [70]. In this line, another work demonstrated that
PNKP-depleted human mitochondrial extracts showed a
significant decrease in both BER and SSBR activities. In
fact, PNKP was found to be the major 3-phosphatase
within mitochondria [71]. Various mtDNA lesions, in-
cluding point mutations and large-scale deletions of
mtDNA, can lead to mitochondrial dysfunction and cel-
lular apoptosis [20]. In fact, mtDNA oxidative stress in-
duces strand breaks with a much higher frequency than
mutagenic lesions [72]. These lesions represent an im-
pairment for both replication and transcription of
mtDNA. When the damage rises above a threshold level,
it can induce degradation of mtDNA molecules [73]. Fu-
ture clinical research should also analyze the mtDNA
damage in DNA repair deficiency, as it could be useful
as a biomarker in patients with mutations in PNKP and
other enzymes from the SSBR pathway.
Mitochondrial dysfunction as a common signature in
cerebellar degeneration
Cerebellar degeneration is a common neurological fea-
ture in ataxia. An interesting fact about the cerebellum
is its extensive development after birth. During this
phase, replication stress is predictable due to the rapid
cell proliferation, leading to more DNA breaks than in
other parts of the nervous system [67]. The cerebellar
degeneration that leads to the ataxia presenting in
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patients with mitochondrial dysfunction can be primary
(caused by affecting the cerebellum and its connections),
or secondary (due to loss of proprioception derived from
peripheral neuropathy or neuronopathy, or a combin-
ation of both) like in spinocerebellar ataxia [74].
Cerebellar development starts with the neurogenesis
of Purkinje cells (PC) around embryonic day E10.5.
Their proliferation ceases shortly before birth, but in the
postnatal period, they still grow, mature and develop
their synaptic network [75]. Purkinje neurons possess
vast numbers of synaptic connections via their dendritic
tree, which implies a high-energy demand for the inte-
gration of excitatory and inhibitory synaptic inputs and
subsequent maintenance of ion gradients. One abnor-
mality in PC mitochondria is observed in the pcd mouse,
a recessive model of neurodegeneration, involving cere-
bellum and retina. It is derived from mutations in the
Agtbp1 gene (Nna1), which expresses a protein that
translocates to mitochondria. Agtbp1 loss of function re-
sults in altered bioenergetics and mitochondrial dysfunc-
tion. As a result, mice present progressive gait ataxia
[76]. Following this idea, we summarize several genes
that are involved in this pathogenic mechanism based
on mitochondrial-related cerebellar degeneration.
Sacs
Autosomal recessive spastic ataxia of Charlevoix-Sague-
nay (ARSACS) is a childhood-onset neurological disease
characterized by cerebellar ataxia with spasticity, pyram-
idal syndrome and peripheral neuropathy. It is caused by
mutations in the SACS gene encoding sacsin. The
knockout mice, display age-dependent neurodegenera-
tion of cerebellar PC due to impaired mitochondrial net-
work and the accumulation of mitochondria in the soma
and proximal dendrites [77].
LIG iii
The inactivation of Lig3 in the mouse nervous system
results in mtDNA loss leading to profound mitochon-
drial dysfunction, disruption of cellular homeostasis and
incapacitating ataxia [78]. Morphological abnormalities
of the mitochondria at postnatal times coincided with
the emergence of ataxia. This was demonstrated in cere-
bellar PC neurons that showed distorted mitochondrial
cristae structure and broad changes in its morphology.
There was also a marked reduction of complex III and
IV immunostaining.
APTX
Although cytoplasmic aprataxin may be present at a low
level in all cell types, it seems to be more predominant
in neuron and neuron-like cell lines and tissues [73].
The expression of the total aprataxin transcript and
aprataxin MTS-encoding transcript varies among the
different brain regions but were more abundant in the
cerebellum. Aprataxin knockdown had a significantly
higher level of ROS than control cells, lower citrate syn-
thase activity, and reduced mtDNA copy number [73].
As the protein has different isoforms (differing from
each other at the N- and C- termini), not every isoform
has the MTS sequence.
TDP1
TDP1 hydrolyzes the phosphodiester bond at a DNA
3′-end linked to a tyrosyl moiety and is involved in the
repair of topoisomerase I (Top1) DNA covalent com-
plexes [79]. A fraction of the TDP1 encoded by the nu-
clear gene translocates to mitochondria [82]. As
mitochondrial base excision repair depends on TDP1 ac-
tivity, it is required for efficient repair of oxidative dam-
age in that organelle [80–82].
Cerebellar neurons and primary astrocytes derived
from Tdp1−/− mice present an inability to rapidly repair
DNA SSBs associated with Top1–DNA complexes or
oxidative damage [83]. Moreover, loss of the protein re-
sulted in age-dependent and progressive cerebellar atro-
phy in spinocerebellar ataxia with axonal neuropathy-1
(SCAN1) patients. The overexpression of a toxic form of
mitochondrial topoisomerase I (TOP1mt*) generates ex-
cessive mitochondrial protein-linked DNA breaks
(mtPDBs), that results in a TDP1-dependent compensa-
tory upregulation of mitochondrial gene transcription.
Misassembled of the ETC complex III resulted in the ab-
sence of TDP1 due to the imbalance in transcription of
mitochondrial- and nuclear-encoded electron transport
chain (ETC) subunits. Bioenergetics profiling further re-
veals that TDP1 promotes oxidative phosphorylation
under both basal and high-energy demands [84].
ATXN1
In cerebellar tissue of a Purkinje cell-driven spinocere-
bellar ataxia type 1 (SCA1), mice display deficits in cere-
bellar OXPHOS complex I (NADH-coenzyme Q
oxidoreductase) [85]. In SCA1, Complex I genes are up-
regulated at the time of onset and upregulation persists
into the late-stage disease.
SCA1 transgenic mice present clinical features of cerebel-
lar dysfunction. The loss of PC is evident in both heterozy-
gous and homozygous six-month-old mice. However,
apoptosis does not seem to be involved in PC degener-
ation. While levels of brain-derived mtDNA are not differ-
ent between SCA1 and control mice, mtDNA levels are
significantly reduced in cerebellum of SCA1 mice [86].
ATXN3
In SCA3, the interaction of PNKP with mutant ATXN3
markedly abrogate PNKP’s enzymatic activity and DNA
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repair efficacy, resulting in persistent accumulation of
strand breaks. Mutant ATXN3 potently activates the
DNA damage-response ATM signaling pathway [26]. In
SCA3, complex II exhibits a consistent tendency toward
decreased activity in the presence of expanded ataxin-3,
particularly in differentiated PC [87]. In neuronal cul-
tures of the cerebellum, striatum and substantia nigra,
the polyglutamine-expanded ataxin-3 (Q79) activates
mitochondrial apoptotic pathway and leads to neuronal
death by upregulating Bax expression and downregulat-
ing Bcl-xL expression of cerebellar, striatal or substantia
nigra neurons [88].
The presence of the full-length mutant ataxin-3 in Q71
homozygotes is either positive in cerebellum and over the
cerebral cortex. However, the fragment and aggregate of
ATXN3 were detected more abundantly in the cerebellum
[89]. Truncated mutant ATXN3 led to more mitochon-
drial fission due to the lower expression of Mfn-1 and
Mfn-2. In transgenic mouse models, truncated mutant
ATXN3 also led to mitochondrial dysfunction, neurode-
generation and cell death in the cerebellum [90].
POLG
In POLG-related neurodegeneration, the primary conse-
quence of POLG mutation in neurons is mtDNA deple-
tion. Progressive accumulation of mtDNA deletions and
point mutations was found accompanied by increasing
numbers of complex I–deficient neurons [91]. Severe
Purkinje and granule cell loss and Bergmann gliosis in
some patients characterized these lesions.
FXN
Friedreich’s ataxia is an autosomal recessive inherited
neurodegenerative disorder, caused by an expansion
mutation within intron 1 of the FXN gene. It is char-
acterized by progressive spinocerebellar ataxia, cardio-
myopathy, scoliosis, and diabetes. The frataxin-
deficient YG8R mouse model showed a limitation of
the maintenance of mitochondrial membrane potential
in cerebellar granule neurons. Specifically, a deficiency
in Complex I increased levels of mitochondrial and
cytosolic ROS. Excessive ROS production results in
oxidative stress and diminishes the level of glutathi-
one (GSH) [92]. Deficient expression of frataxin leads
to deleterious alterations in iron metabolism in the
mitochondrial matrix that is presumed to play a cru-
cial role in the oxidative damage and subsequent de-
generative features of this disease [93].
Despite the known role of mitochondria dysfunction
in cerebellar degeneration that usually leads to ataxia, it
is not clear why diseases such as POLG and Friedreich’s
ataxia occur with many systemic clinical manifestations.
Interestingly, ataxia associated with mitochondrial dys-
function seems to be the primary clinical manifestation,
if caused by mutations in the enzymes of the SSBR
pathway.
ATM
Ataxia-telangiectasia (AT) has been the archetypal neuro-
logical disorder associated with DNA double-strand break
repair, mainly because of its predisposition to cancer [94].
The disease has an extended phenotype, as a cause of the
dual function of ATM: DNA repair and regulation of oxi-
dative stress and mitochondrial homeostasis. Although
AT presents defects in DNA repair and mitochondrial
dysfunction, the clinical manifestations have a systemic
pattern. Thus, the pathological role of DNA repair defi-
ciency in AT seems to extend to all cells in the body,
which explains the predisposition to cancer, something
rarely seen in other types of ataxia. In contrast, the
mitochondrial dysfunction seems to be more crucial in
neurons, especially in the cerebellum as recently demon-
strated [95–97] (Fig. 4).
In some other the diseases caused by mutations in
DNA repair enzymes, there was no clarity regarding the
possible mitochondrial involvement. Recently, in Xero-
derma pigmentosum A (XPA), a disease characterized by
dermatological ailments but also progressive cerebral
and cerebellar atrophy, sensorineural hearing loss and
neuropathy, mitochondrial dysfunction was shown. The
dysfunction seems to originate from defects in mito-
phagy, possibly mediated by hyperactivation of PARP1
[98–100]. Another interesting case is a recent report of a
patient with mutations in XRCC1 who presented motor
ocular apraxia, axonal neuropathy, and progressive cere-
bellar ataxia [101]. In this case, the authors also deter-
mined that hyperactivation of PARP1 was the cause of
cerebellar ataxia. To understand the implication of this
pathway in the mitochondrial dysfunction, it is also im-
portant to examine the PARP1/NAD+/SIRT1 axis. When
PARP1 is activated, it orchestrates DNA repair, which
leads to the loss of NAD+ and acetyl-CoA. This results
in inhibition of SIRT1 that leads to an increase in mito-
chondrial ROS, owing to decreased activation of stress
response factors such as AMPK, FOXOs, and PGC1α.
Also, SIRT1 has been shown to regulate several DNA re-
pair pathways positively; including xeroderma pigmento-
sum group A-complementing protein (XPA), KU70,
ataxia telangiectasia mutated (ATM) and thymine DNA
glycosylase (TDG) [102]. In this regard, PARP1 appears
as a common potential therapeutic target for mitochon-
drial dysfunction in DNA repair disorders.
Principles of DNA repair deficiency disorders
DNA repair deficiencies (DRD) result from different mu-
tations in DNA repair enzymes. There are critical con-
siderations to understand the molecular basis of several
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neurological diseases, and therefore, for establishing the
correlation between the genotype and phenotype. From
the available data, here we summarize the interactions of
a group of elements that combined, can explain the mo-
lecular pathogenesis of these diseases.
The first consideration that should be taken into ac-
count is whether a pathological tropism (PT) is observed
in the disease. PT can be understood as the tendency of
a disease to affect a particular tissue. In the case of the
SSBR pathway, it would mean an exclusive neurological
effect [21]. This is possibly explained by the vulnerabil-
ities of the nervous system regarding higher oxidative
damage and higher dependence on DNA repair, com-
pared to the rest of the body.
DRD neurological disorders can be divided into those
affecting the neurons during development and the ones
that affect the mature nervous system. In the process of
neurogenesis, the replication stress associated with high
Fig. 4 Genotype and phenotype correlation according to the type of mitochondrial damage. DSBR is involved in neurodevelopmental impairment
without mitochondrial involvement evidence (a), whereas neurodegenerative disorders proceed from SSBR deficiency or mitochondrial homeostasis
dysfunction. In SSBR related diseases, the protein variants cause an indirect effect on mitochondria that lead to exclusively neurological impact
characterized mainly by peripheral neuropathy and cerebellum atrophy (b). On the other hand, mutations associated with mitochondrial functioning
itself have direct systemic implications (c). Although both clinical categories have mitochondrial involvement, DNA repair deficiency is the primary
cause of neuropathological tropism (discussed later). MIRAS: mitochondrial recessive ataxia syndrome / MELAS: mitochondrial myopathy
encephalopathy lactic acidosis and stroke
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rates of proliferation is a major source of DNA damage
that can perturb neural development. Indeed, it can be
the main etiology involved in neurodevelopmental dis-
ease. On the other hand, in the mature nervous system
(post-mitotic cells) the high transcriptional activity asso-
ciated with metabolism result in cell dysfunction and
possibly death.
The next consideration to comprehend the specific
pathology related to a mutation is the momentum, which
is the stage of cellular development when the damage
occurs. In the case of neurons, it can be mitotic or
post-mitotic. Neurodevelopment-associated damage is
more likely to originate in the mitotic momentum, and
neurodegenerative diseases would begin principally
post-mitotic. This is relevant to understand and classify
the pathologies of the central nervous system. We sug-
gest a more in-depth evaluation of the categories estab-
lished for DRD disorders, especially those that appear to
arise in the development but has neurodegenerative im-
plications. Evidence indicates that AOA causative muta-
tions affect the development of Purkinje cells through
the impairment of mitochondrial homeostasis. Neverthe-
less, clinical manifestations occur in the first decade and
progress through life, showing a neurodegenerative path-
ology. Momentum matters, since the most common
types of DNA damage in the nervous system, are differ-
ent at both stages, just like the repair systems available.
In developing cells, the most important source of errors
is the DNA replication itself. As we explained before, in
post-mitotic neurons, the main source of mutations is
the stress associated with transcription and the
high-energy demand, in which the mitochondria are in-
volved, primarily due to the ROS production [68]. This
is what we define as the source of mutagenic damage.
The damage derived from mitotic cells is predomin-
ately double-strand breaks (DSBs), normally repaired by
homologous recombination and the NHEJ (PNKP
+XRCC4 complex). If breaks cannot be repaired, it
would be lethal at this stage through apoptosis. In
post-mitotic neurons, non-homologous end joining
(NHEJ) is the sole pathway available to prevent accumu-
lation of DNA double-strand breaks [103]. On the other
hand, SSBs represent a serious threat to genetic stability
and cell survival, especially because neurons have low
levels of antioxidant enzymes and high metabolic activ-
ity. Proliferative cells become increasingly dependent on
SSBR, and post-mitotic cells depend on SSBR exclu-
sively, in which PNKP has a crucial role, especially in
mitochondria-derived oxidative stress damage [11, 13].
In mature cells, the high frequency of error linked to
SSBs and the lack of alternative pathways, especially in the
mitochondria, could lead to an accumulation of damage.
This may explain the late onset and slow progression of
neurodegenerative diseases. Therefore, depending on the
momentum and source, it is possible to classify the specific
type of error in DNA: this can be defined as the principle
of the (single or double) affected strand.
As observed for PNKP, XRCC1 is required in the
neurogenesis of cerebellar interneuron [104]. XRCC1 de-
ficiency drives a progressive and persistent accumulation
of strand breaks in mature neuronal populations. Ac-
cording to this, it is possible to notice an overlap be-
tween the phenotype caused by mutant variants from
the same pathway (SSBR), especially in the impaired de-
velopment of the cerebellum. It could be hypothesized
that the clinical spectrum can also be related to the level
of disruption in the SSBR cascade.
Since PNKP could share the same mutations in both
neurodevelopmental and neurodegenerative diseases, the
problem cannot be referred to the protein variant itself,
but how the PNKP mutant interacts with the available
repair machinery for a specific momentum and strand.
This can be synthesized as the effect of the mutation in
the enzyme and the particular pathway involved that ul-
timately leads to a specific phenotype. In tissues like the
cerebellum where mutations arise with a very high rate
(due to the high proliferation rate), and axons, where the
energy demand is so high that it compromises mito-
chondrial homeostasis, mutations in DNA repair en-
zymes could lead to the observed neurodegenerative
phenotype. Thus, at this point, it is possible to integrate
the mitochondrial dysfunction in both axonal and cere-
bellar degeneration and introduce the last principle or
consideration: mitochondrial intervention.
Since the energetic requirement of neurons is very high,
axons contain more mitochondria than other cellular do-
mains. This mitochondrial activity generates a high
amount of ROS with the subsequent SSBs. The cerebel-
lum cells, such as PC, have a high rate of postnatal replica-
tion, which is highly dependent on mitochondrial activity.
Most diseases with ataxia as primary clinical manifestation
due to mutations in DNA repair enzymes (SSBR) present
an indirect effect of mitochondrial function (Fig. 4b).
Therefore, although the primary damage is more likely to
derive from unrepaired nuclear DNA damage (associated
with replication stress), there is a concomitant role between
nuclear and mitochondrial genome dysfunction as the
underlying pathogenic process. According to this, we
propose a model in which mutations in DNA repair en-
zymes such as PNKP, APTX, TDP1, ATXN1/3, and others,
cause an indirect effect on mitochondria that lead to exclu-
sively neurological impact due to the specific metabolic and
genome maintenance characteristics of the central nervous
system. This damage is mainly peripheral neuropathy and
cerebellum atrophy, showing an evident mitochondrial
SSBR-dependent dysfunction (Fig. 4b). To determine the
moment in which the mitochondrial damage occurs could
be important for a future therapeutic approach.
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Diseases such as Friedreich’s ataxia and MIRAS
(caused by POLG mutations) present an extended
phenotype, maybe derived from the equal vulnerability
that these variants confer to the mitochondria in the
whole organism. Even though the clinical difference is
evident, still more research is needed to understand
the molecular basis of this systemic damage compared
with the diseases that tend to present a pathological
tropism. One idea is that mtDNA often shows an un-
even distribution between cells of the same tissue, so
this can explain why defects appear only above a
mutation-specific threshold in vulnerable organs. This
can generate a mosaic pattern of mitochondrial dys-
function and differences in the distribution patterns
of the pathogenic mutations can be observed and be
clinically relevant [36].
Conclusions
Deficiency in DNA repair can lead to multiorgan diseases
or can be confined to the nervous system. Enzymes such
as PNKP, TDP1, and APTX, are not only active in the nu-
cleus of neurons but also in their mitochondria. They con-
stitute an example of how the deficiency in the DNA
SSBR machinery converges with mitochondrial dysfunc-
tion, in the etiology of pathologies with an exclusive
neurological involvement. There is enough evidence to
conclude that mitochondrial dysfunction is what best ex-
plains the clinical manifestations and progression in neu-
rodegeneration. Therefore, intensive research should be
directed to develop new therapeutic strategies, targeting
the common feature of these diseases: the mitochondria.
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